Medicine: latest AI news

AI in medicine and biology: approvals, trials, studies and products, linked to regulators and journals.

2 Nov Tempus AI reports $411.5 million of third-quarter revenue, up 23%, and raises its 2026 forecast
2 Nov AI guidance lets staff with no ultrasound training capture quality heart scans in rural mobile clinics
2 Nov AI reading home blood-pressure cuff and wrist-tracker data flags hypertensive crises up to three days early
1 Nov P4 trial: CT-guided stent planning with Heartflow's AI tools matches IVUS outcomes at one year
1 Nov Chinese Institute for Brain Research starts three national major projects on implantable brain-computer interfaces
31 Oct Review finds AI models for myeloproliferative neoplasms accurate in cohorts but none tested in interventional trials
31 Oct An AI agent picks a gene therapy and drives a robotic injection into a live mouse's brain, Exin says
31 Oct Manitoba researchers test ORION, an AI model to rework surgery scheduling and cut backlogs
31 Oct University of Manitoba to test ORION, an AI system that predicts surgical demand and schedules operating rooms
31 Oct AI-designed peptide RK-14 kills MRSA and drug-resistant E. coli and clears catheter biofilms in lab tests
30 Oct OpenAI releases GPT-Rosalind-6, a life-sciences model with fewer dual-use biology refusals to vetted groups only
30 Oct FDA grants accelerated approval to Inovio's Voceryq, the first US plasmid DNA immunotherapy, for adult RRP
30 Oct PopVax launches personalized mRNA cancer vaccine manufacturing at its Hyderabad RNA Foundry
30 Oct Proposed class action says AHN and Highmark used Abridge's AI scribe to record patient visits without proper consent
30 Oct Biotech investor Bruce Booth predicts AI drug design will worsen pharma R&D productivity for three to five years
30 Oct Musk says Neuralink's Blindsight vision implant is ready and awaiting regulatory approval
30 Oct Self-improving agent MoLRSI hits 15.9% in antibiotic screening versus 8.7% for an expert workflow
29 Oct Nature Medicine study reports one explainable AI model diagnosing across 10 medical imaging modalities
29 Oct Parse Biosciences and Nomic plan Cascade, a 100-million-cell immune dataset for training AI models
29 Oct Agentic AI system detects immunotherapy side effects in clinical notes with F1 of 0.92, Nature Cancer study finds
29 Oct Lilly's retatrutide beats Ozempic head-to-head, with 20.9% weight loss versus 9.4% in type 2 diabetes
29 Oct Lilly raises 2026 revenue guidance to $91–92 billion as third-quarter revenue rises 39%
29 Oct Simulation-trained language model agent more than halves under-triage of acute risks in psychiatric intake tests
28 Oct Genmab's petosemtamab plus pembrolizumab halves risk of death in Phase 3 head and neck cancer trial
28 Oct Preprint finds 15 language models catch more planted errors in clinical trial reports than human peer reviewers
27 Oct FDA draft guidance would let one license cover many patient-specific gene-editing variants
26 Oct FDA approves talazoparib plus enzalutamide for earlier HRR-mutated metastatic prostate cancer
22 Oct FDA accepts Biohaven's resubmitted application for troriluzole in spinocerebellar ataxia
21 Oct UK launches AD-SMART, a Phase 3 platform trial repurposing metformin and atomoxetine for Alzheimer's
20 Oct OpenAI acquires Orchestra Bio to bring drug-development tracking into its Rosalind suite
20 Oct Rapport's RAP-219 meets Phase 2 endpoints in acute bipolar mania
19 Oct FDA grants accelerated approval to dostarlimab for dMMR locally advanced rectal cancer
19 Oct Disc Medicine's bitopertin meets all endpoints in Phase 3 APOLLO for erythropoietic protoporphyria
16 Oct FDA converts Keytruda's tumor-agnostic TMB-high approval to full approval but narrows the cutoff
16 Oct FDA approves Viatris's Ryzumvi eye drops for presbyopia in adults
16 Oct FDA approves self-administered autoinjector for UCB's myasthenia gravis drug Zilbrysq
14 Oct Arrowhead's RNAi drug ARO-MAPT cuts spinal-fluid tau by up to 73% in healthy volunteers
14 Oct Bristol Myers says actinium-225 therapy RYZ101 meets Phase 3 progression-free survival goal
12 Oct Randomized trial finds Myosuit soft exosuit training does not beat standard therapy overall after stroke
9 Oct FDA approves Teva's Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia
8 Oct Life Biosciences reports first-in-human safety data for ER-100 epigenetic reprogramming therapy
7 Oct FDA approves tucatinib with trastuzumab and pertuzumab as HER2-positive breast cancer maintenance
5 Oct Deisseroth, Hegemann and Nagel win the 2026 Nobel Prize in medicine for optogenetics